XML 75 R47.htm IDEA: XBRL DOCUMENT v3.25.4
Revenue Recognition (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2014
Disaggregation of Revenue [Line Items]        
Total net revenue $ 411,328 $ 358,711 $ 310,463  
Milestone fees paid 220,000 220,000    
Net product sales        
Disaggregation of Revenue [Line Items]        
Total net revenue 172,130 97,492 $ 60,617  
U.S.        
Disaggregation of Revenue [Line Items]        
Milestone fees paid $ 120,000 $ 120,000    
Net Product Sales | Geographic Concentration Risk | U.S.        
Disaggregation of Revenue [Line Items]        
Concentration Risk, Percentage 69.00% 83.00% 91.00%  
Net Product Sales | Geographic Concentration Risk | Rest of the world        
Disaggregation of Revenue [Line Items]        
Concentration Risk, Percentage 31.00% 17.00% 9.00%  
GSK | Long-Acting Beta2 Agonist (LABA) Collaboration        
Disaggregation of Revenue [Line Items]        
Milestone fees paid       $ 220,000
GSK | RELVAR/BREO | Long-Acting Beta2 Agonist (LABA) Collaboration        
Disaggregation of Revenue [Line Items]        
Royalty rate for first level of annual global net sales (as a percent) 15.00%      
Annual global sales level used to determine royalty rate $ 3,000,000      
Royalty rate for sales above first level of annual global net sales (as a percent) 5.00%      
GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum        
Disaggregation of Revenue [Line Items]        
Royalty rate for combination products (as a percent) 6.50%      
GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum        
Disaggregation of Revenue [Line Items]        
Royalty rate for combination products (as a percent) 10.00%